MX2018015188A - Lipidos con un numero impar de atomos de carbono y su uso como una composicion farmaceutica o como un suplemento nutricional. - Google Patents

Lipidos con un numero impar de atomos de carbono y su uso como una composicion farmaceutica o como un suplemento nutricional.

Info

Publication number
MX2018015188A
MX2018015188A MX2018015188A MX2018015188A MX2018015188A MX 2018015188 A MX2018015188 A MX 2018015188A MX 2018015188 A MX2018015188 A MX 2018015188A MX 2018015188 A MX2018015188 A MX 2018015188A MX 2018015188 A MX2018015188 A MX 2018015188A
Authority
MX
Mexico
Prior art keywords
diseases
lipids
carbon atoms
odd number
nutritional supplement
Prior art date
Application number
MX2018015188A
Other languages
English (en)
Spanish (es)
Inventor
Dong Yuhong
Hsiung Chang Chun-
Lin Shengtang
Original Assignee
Sunregen Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunregen Healthcare Ag filed Critical Sunregen Healthcare Ag
Publication of MX2018015188A publication Critical patent/MX2018015188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
MX2018015188A 2016-06-08 2017-06-06 Lipidos con un numero impar de atomos de carbono y su uso como una composicion farmaceutica o como un suplemento nutricional. MX2018015188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347103P 2016-06-08 2016-06-08
PCT/CN2017/087341 WO2017211274A1 (en) 2016-06-08 2017-06-06 Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Publications (1)

Publication Number Publication Date
MX2018015188A true MX2018015188A (es) 2019-08-21

Family

ID=60577583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015188A MX2018015188A (es) 2016-06-08 2017-06-06 Lipidos con un numero impar de atomos de carbono y su uso como una composicion farmaceutica o como un suplemento nutricional.

Country Status (12)

Country Link
US (2) US11406616B2 (https=)
EP (1) EP3468551A4 (https=)
JP (2) JP6872805B2 (https=)
KR (1) KR20190017873A (https=)
CN (2) CN117298092A (https=)
AU (1) AU2017277005B2 (https=)
CL (1) CL2018003537A1 (https=)
MX (1) MX2018015188A (https=)
NZ (1) NZ749389A (https=)
SG (1) SG11201810580PA (https=)
TW (1) TWI749016B (https=)
WO (1) WO2017211274A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
CN111773351A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及姜黄组合物在制备降血糖及降血压的药物组合物中的应用
CN111773274A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及车前子组合物在制备降血糖及降血压的药物组合物中的应用
JP7685134B2 (ja) * 2019-11-27 2025-05-29 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品
WO2022263624A1 (en) * 2021-06-18 2022-12-22 Sunregen Healthcare Ag Novel compounds for the treatment and prevention of neurological complications of viral infections
JP2023061448A (ja) * 2021-10-20 2023-05-02 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
US20260060952A1 (en) * 2022-10-02 2026-03-05 Refine Holdings Co., Ltd. Prophylactic, Progression Inhibitor, Ameliorant for Visual Field Defect Disorders, Light-Induced Ocular Tissue Disorders and Related Disorders, and Food Product

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS558351A (en) 1978-07-05 1980-01-21 Hitachi Ltd Press machine
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
JPS5919775U (ja) 1982-07-26 1984-02-06 ワイケイケイ株式会社 カ−テンウオ−ルの断熱窓
CA1244772A (en) 1983-06-21 1988-11-15 Kuniaki Adachi Cell-stimulating composition
JPH02247125A (ja) 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
JP3558351B2 (ja) 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
DE19821003A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020006959A1 (en) 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
AU2001264079A1 (en) 2000-06-14 2001-12-24 William Leslie Porter Lipids for modulating immune response
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
JP5026655B2 (ja) 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
CN1764446A (zh) * 2003-03-13 2006-04-26 康福玛医药公司 含有长链和中链甘油三酯的药物制剂
US8399515B2 (en) 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
JP4334956B2 (ja) 2003-09-18 2009-09-30 株式会社ノエビア 細胞賦活剤、美白剤、及び抗酸化剤
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
CA2700431A1 (en) 2006-09-26 2008-04-03 Baylor Research Institute Use of odd-chain fatty acids in the modulation of cellular catabolism
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
KR100829729B1 (ko) 2007-01-29 2008-05-15 한불화장품주식회사 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물
PT2299998T (pt) 2007-11-02 2018-04-02 Prometic Pharma Smt Ltd Acidos gordos e glicerídeos de cadeia média como agentes nefroprotetores
DE102008046227A1 (de) * 2008-06-10 2009-12-17 Ludwig-Maximilians-Universität München Hochdurchsatzmethode zur Analyse der Fettsäurezusammensetzung in Plasmaphosphoglyceriden
DE102008057867A1 (de) * 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN101879156B (zh) 2009-05-07 2013-01-30 上海医药工业研究院 一种药物组合物及其应用
KR20120129898A (ko) 2009-12-30 2012-11-28 베일러 리서치 인스티튜트 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법
MX337605B (es) * 2010-01-08 2016-03-10 Catabasis Pharmaceuticals Inc Derivados de fumarato de acido graso y sus usos.
CN102883733B (zh) * 2010-02-10 2014-08-13 奥力榨油化株式会社 Age生成抑制剂
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
JP2013528648A (ja) 2010-06-14 2013-07-11 ベイラー リサーチ インスティテュート 成人ポリグルコサン小体病（ａｐｂｄ）を処置するためのトリヘプタノイン食
EP2407155B1 (en) * 2010-07-15 2012-12-26 Hybrigenics S.A. Formulations of inecalcitol
CN103945840A (zh) 2011-08-26 2014-07-23 国立大学法人大阪大学 糖尿病性心血管并发症的预防/治疗剂
CN102526643B (zh) * 2012-03-22 2013-09-11 常熟市虞山绿茶有限公司 一种治疗口腔溃疡的中草药含片
CA2894456C (en) 2012-12-13 2022-06-28 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
CN117502539A (zh) * 2013-08-02 2024-02-06 施韦特-莫迪国际公司 包含经重构植物材料的可食用产品
ES2774321T3 (es) 2013-11-14 2020-07-20 Univ Queensland Trastornos neurodegenerativos y métodos de tratamiento y diagnóstico de los mismos
CN103641713B (zh) 2013-11-15 2015-10-21 浙江大学 甘油单酯衍生物的制备方法及应用
WO2015110977A1 (en) 2014-01-22 2015-07-30 Rolexi Marketing (Pty) Ltd Fatty acid composition and medicinal use thereof
CN104286296A (zh) * 2014-09-25 2015-01-21 王美华 一种凉茶
JP6406978B2 (ja) 2014-11-04 2018-10-17 株式会社シー・アクト 脂肪酸混合物
CN105267501A (zh) * 2015-11-04 2016-01-27 夏茂森 一种治疗毒蛇咬伤的中药组合物
CN105381182A (zh) 2015-11-20 2016-03-09 冯天寿 一种治疗慢性荨麻疹的中药及其应用
EP3383382A1 (en) 2015-12-04 2018-10-10 Nestec S.A. Method for improving cognition

Also Published As

Publication number Publication date
CN117298092A (zh) 2023-12-29
JP2021113204A (ja) 2021-08-05
WO2017211274A1 (en) 2017-12-14
NZ749389A (en) 2022-12-23
EP3468551A4 (en) 2020-01-22
CL2018003537A1 (es) 2019-05-03
AU2017277005A1 (en) 2019-01-17
AU2017277005B2 (en) 2022-12-22
CA3026152A1 (en) 2017-12-14
KR20190017873A (ko) 2019-02-20
US20190255129A1 (en) 2019-08-22
CN110300581B (zh) 2023-09-08
EP3468551A1 (en) 2019-04-17
JP6872805B2 (ja) 2021-05-19
US11406616B2 (en) 2022-08-09
US20220362197A1 (en) 2022-11-17
SG11201810580PA (en) 2018-12-28
US12594255B2 (en) 2026-04-07
CN110300581A (zh) 2019-10-01
TWI749016B (zh) 2021-12-11
JP2019518034A (ja) 2019-06-27
TW201801720A (zh) 2018-01-16

Similar Documents

Publication Publication Date Title
MX2018015188A (es) Lipidos con un numero impar de atomos de carbono y su uso como una composicion farmaceutica o como un suplemento nutricional.
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
WO2017070647A8 (en) Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)
WO2015139051A3 (en) Nanocarriers and their processing for diagnostics and therapeutics
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA49339A (fr) Conjugués insuline-fc à extension oligomère
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
EP4406536A3 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
WO2018154118A3 (en) Aromatic compounds which enhance notch signaling, for use in therapy
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
WO2020039088A3 (en) Aromatic molecules for use in the treatment of pathological conditions
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
PH12020500511A1 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
WO2020039092A3 (en) Aromatic molecules for use in the treatment of pathological conditions
RU2017123243A (ru) Состав, содержащий экстракт кожицы poria cocos, предназначенный для профилактики, облегчения состояния и лечения нейродегенеративных расстройств
WO2015073813A3 (en) Treatment of diseases involving the hippo pathway
WO2014028768A3 (en) Evaluation of duf1220 copy number and methods of using the same
Ruan et al. Blood-brain barrier permeability of DIF and its elimination comparative study between brain and peripheral tissues in Carassius auratus gibelio
Soares et al. Reflections about the perception of therapeutic environment in clients and therapists: The importance of the 5th session.
Barbe Levodopa/benserazide/pramipexole
Kim Nonconvulsive status epilepticus: case report